title: Changes in human immunodeficiency virus type 1 virus load during mobilization and harvesting of hemopoietic progenitor cells. Adult AIDS Clinical Trials Group 285 Study Team.
abstract: Genetic modification of hemopoietic progenitor cells ex vivo, followed by the infusion of the genetically modified cells into the human immunodeficiency virus-1 (HIV-1) infected donor, has been proposed as a treatment for HIV-1 infection. The current study was undertaken to evaluate the effect of hemopoietic stem cell mobilization and harvesting on HIV-1 replication in persons with HIV-1 infection. Eighteen HIV-1-infected persons received recombinant granulocyte colony-stimulating factor (G-CSF; Filgrastim) 10 microg/kg per day, for 7 days. On days 4 and 5, peripheral blood mononuclear cells were harvested by leukapheresis. The CD4+ lymphocyte count at entry was >500/microL for 6 subjects, 200 to 500/microL for 6 subjects, and <200/microL for 6 subjects. For 9 of 18 subjects, plasma HIV-1 RNA levels increased 4- to 100-fold (>0.6 log(10)) above baseline between days 4 and 7 and returned to baseline by day 27. Significant increases of plasma HIV-1 RNA levels occurred in 5 subjects despite 3-drug antiretroviral therapy. Changes in CD4+ and CD34+ cells during mobilization and harvesting were similar in all subjects whether they had or did not have increased plasma HIV-1 RNA levels. Thus, mobilization and harvesting of bone marrow progenitor cells from persons infected with HIV-1 induced a transient increase in viral replication in some patients but was not associated with adverse effects. (Blood. 2000;95: 48-55)
authors.affiliation: University of Colorado Health Sciences Center and Bonfils Blood Center, Denver, CO 80262, USA. thomas.campbell@uchsc.edu
authors.forename: T B
authors.initials: TB
authors.lastname: Campbell
authors.forename: A
authors.initials: A
authors.lastname: Sevin
authors.forename: R W
authors.initials: RW
authors.lastname: Coombs
authors.forename: G C
authors.initials: GC
authors.lastname: Peterson
authors.forename: M
authors.initials: M
authors.lastname: Rosandich
authors.forename: D R
authors.initials: DR
authors.lastname: Kuritzkes
authors.forename: J
authors.initials: J
authors.lastname: Mladenovic
authors.forename: A
authors.initials: A
authors.lastname: Landay
authors.forename: R
authors.initials: R
authors.lastname: Wong
authors.forename: D
authors.initials: D
authors.lastname: Ambruso
authors.forename: S
authors.initials: S
authors.lastname: Miles
authors.forename: R J
authors.initials: RJ
authors.lastname: Pomerantz
authors.forename: R T
authors.initials: RT
authors.lastname: Schooley
mesh_terms: D000328:Adult; D018791:CD4 Lymphocyte Count; D015331:Cohort Studies; D004279:DNA, Viral / Q000097:blood; D000069585:Filgrastim; D016179:Granulocyte Colony-Stimulating Factor / Q000627:therapeutic use*; D015658:HIV Infections / Q000097:blood* / Q000276:immunology / Q000628:therapy; D015497:HIV-1 / Q000302:isolation & purification*; D019650:Hematopoietic Stem Cell Mobilization; D006412:Hematopoietic Stem Cells / Q000473:pathology*; D006801:Humans; D007937:Leukapheresis; D008214:Lymphocytes / Q000821:virology*; D008297:Male; D008875:Middle Aged; D018579:Patient Selection; D012367:RNA, Viral / Q000097:blood; D011994:Recombinant Proteins; D019562:Viral Load
chemical_list: D004279:DNA, Viral; D012367:RNA, Viral; D011994:Recombinant Proteins; D016179:Granulocyte Colony-Stimulating Factor; D000069585:Filgrastim